BB's Stock Haven

[albert]

Pilot Study for HPB-84 Shows Positive Results for Diabetes Sufferers
Tuesday June 28, 11:41 am ET
Participants Lowered Glucose Levels, Reduced Dependence on Medication


HUTCHINSON, Kan., June 28 /PRNewswire-FirstCall/ -- Patients participating in a 12-week pilot study for the Type II diabetes supplement HPB-84 successfully reduced blood glucose levels as well as their dependence on oral medication, reported HEE Corporation (OTC: HCCF - News), the manufacturer of HPB-84.
ADVERTISEMENT



The pilot study, which involved 10 test subjects, was conducted to evaluate the efficacy of HPB-84, the breakthrough nutraceutical that safely and effectively addresses the three major issues of Type II diabetes by reducing blood sugar levels and insulin resistance while promoting insulin production. The average participant showed a 26.9 percent decrease in fasting blood glucose levels, and an average of 16 percent decrease in hemoglobin A1C. Prior to the trial, nine of the 10 participants took oral medication and two of the patients were insulin dependent. Four of the nine participants were able to lessen their oral medication, and of the two taking insulin, one reduced the amount taken, while the other was able to completely stop taking insulin.

"We're delighted to see that HPB-84 is having a real, positive impact on the lives of people with Type II diabetes," said Radley Brooks, president of HEE Corp. "Participants and their doctors are encouraged by the results, and people are telling us they feel better than they have in years."

The active ingredients in HPB-84 address the causes of diabetes to improve the quality of life. The ingredients, generally recognized as safe (GRAS) by the FDA, include bitter gourd, naja jihwa, jambul, fenugreek, bengal quince, gurmar and cinnamon. Recent clinical studies show no adverse drug interaction with HPB-84, but it is recommended that customers consult with physicians to determine the proper initial dosage.

Researchers found a number of individual success stories in the trial. One 66-year-old Caucasian male had been a Type II diabetic for thirteen years. At the beginning of the study, he was taking 14 medications and 130-140 units of insulin per day. By the end of the study, he was taking only six medications, no longer required insulin injections, and his fasting blood glucose level fell from a range of 124-155 to 99-134. A second participant reduced his average fasting blood glucose level to 110 from 270, lost 18 pounds, and is now taking half the dosage of his prescription medications.

Most Type II diabetes patients will start seeing positive results from taking HPB-84 within a short period of time, sometimes within a week, but results vary depending on the severity of symptoms, prescription medication and weight. As part of a comprehensive diabetes management program, HEE Corp recommends that diabetes patients talk with their physician, diabetic clinician and nutrition professional to closely monitor their weight, diet and glucose levels while taking HPB-84. HPB-84 is sold exclusively through the Web site http://www.hpb84.net .

About HEE

Founded in Hutchinson, Kansas in December 2003, HEE Corporation (OTC: HCCF - News) is a publicly-traded company committed to improving the quality of life through the research, development and distribution of products, services and nutraceuticals that address many of the causes of metabolic syndrome. Metabolic syndrome is quickly being recognized by the medical community as one of the most prevalent health conditions in the United States. HPB-84, manufactured in the United States, is currently sold exclusively through http://www.hpb84.net . It contains a proprietary blend of the following ingredients generally recognized by the FDA as safe (GRAS). Complete company and investor information can be found at the company Web site, http://www.hee-corp.com .

Forward-Looking and Cautionary Statements

Statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the company's filings with the Securities and Exchange Commission. HEE Corporation undertakes neither intention nor obligation to publicly update or revise any forward-looking statements. HEE Corporation and the HEE Corporation logo are trademarks or registered trademarks.


Contact: Mark Bouffard
media imPRessions/HEE Corporation
312.222.9590
[e-mail]


BUY BUY 15 julie 0.04